8:00 am
Registration & Morning Coffee

8:25 am
Chair’s Opening Remarks

Deciphering Key Learnings & Principals from Trailblazing Inflammasome Drugs

8:30 am Panel Discussion: Industry Leader Perspectives on Inflammasome Therapeutic Development & Commercialization

  • Stephen Glover Co-Founder, Chairman & Chief Executive Officer, ZyVersa
  • Adam Keeney Chief Executive Officer, NodThera
  • Anil Goyal Chief Executive Officer & Board Director, IMMvention Therapeutix


  • Exploring recent deals in the space: How to raise capital, attract investors and large pharma interest
  • Thinking outside the box when it comes to prioritizing specific disease indications for specific inflammasome therapeutics
  • How to balance commercial considerations of drug development with unmet need across diseases?
  • How crucial is it to demonstrate differentiation from standards of care or other inflammasome inhibitors to
    regulators and investors?
  • Should you plan for comparative data with standards of care in preclinical models before selecting indications
    and comparing across modalities?
  • Thoughts on evidence that activation of more than one type of NLR is pathogenic – are people going to take
    different directions to drug development now?

9:00 am A Phase 1b Study to Test the Safety, Pharmacokinetics, & Pharmacodynamics of a Novel NLRP3 Inflammasome Inhibitor in Early- Stage Parkinson’s Disease


  • Hear about the first study of Selnoflast in participants with early idiopathic PD
  • Characterizing a new compound targeting NLRP3 inflammasome
  • Exploring innovative Ph1b design to test safety, pharmacokinetics and pharmacodynamics

9:30 am Discovery, Characterization, & Advancement, of Novel Chemotypes of Potent & Selective Brain Penetrant & Peripherally Restricted NLRP3 Inhibitors

  • Anick Auger Head of In Vitro & In Vivo Pharmacology, Ventus Therapeutics


  • Exploring the drug discovery process: target identification and validation,
    efficacy, pathway understanding and biomarkers
  • Discussing biomarker and patient status
  • Reviewing latest data and future directions

10:00 am Using Machine Learning to Harness the Complexities of Inflammasome Biology for Novel Drug Discovery

  • Christian Elabd Vice President, Research & Development , Spring Discovery


  • Training machine learning algorithms to identify different states of inflammasome activation and inhibition in human primary PBMCs
  • Combining these algorithm predictions with traditional readouts from imaging data and secreted protein profiling data in order to obtain a full picture of these states of inflammasome activation and inhibition
  • Capturing and analyzing all of these data from a single well, enabling us to characterize, score, and nominate hits from large compound libraries

10:30 am
Morning Refreshments & Poster Session


This is an informal session to help you connect with your peers in a relaxed atmosphere and continue forging new and beneficial relationships. You will have the opportunity to present your work, and review presentations displaying novel approaches and findings

Molecular Underpinnings of Inflammasome Dysregulation

11:30 am Recent Insights Into NLRP1 & CARD8 Inflammasome Activation


  • Review the impact of reductive stress on inflammasome activation
  • Discuss the impact of XP peptide accumulation on inflammasome activation
  • Find potential links between reductive stress and XP peptides

12:00 pm The Role of Secretoglobins in Inflammasome Responses


Session details to be announced.

Inflammasome Pathway Targets Downstream of Inflammasome Activation

12:30 pm Novel ASC Antibodies Reduce Inflammasome Activation And Propagation Of Inflammation In Vitro & In Vivo


  • Explore a panel of high affinity monoclonal antibodies
    was generated against different regions of ASC
  • Learn how these mAbs inhibit ASC polymerization and
    mitigate inflammation propagation in vitro
  • Discover how selected mAb improved functional
    outcomes in a mouse model of neuroinflammation

Advances in Proof-of- Concept Trials & Moving Towards the Clinic

11:30 am ADS032: A Novel Dual NLRP1 & NLRP3 Inhibitor to Target Inflammasome Inflammation


  • Learn about ADS032, a novel dual inflammasome inhibitor
  • Discover how ADS032 reduces inflammation both in vitro and in vivo
  • Evaluate how ADS032 reduces the inflammatory burden during inflammasome-related disease

12:00 pm First in Human Dosing of HT-6184, a Novel Allosteric NEK7 Inhibitor Targeting NLRP3 Assembly & Function


  • Explore how targeting the ability of Nek7 to bind to NLRP3 blocks and activation and promotes disassembly of the NLRP3 Inflammasome
  • Review how HT-6184 potently blocks NLRP3 activity and function
  • Evaluate data on the PK and PD of HT-6184 in the firstin- human trial that will be presented

12:30 pm An Update on the Monogenic Inflammasomopathies with a Focus on CAPS

  • Hal Hoffman Professor of Pediatrics & Medicine & Chief of the Division of Allergy, Immunology and Rheumatology in the Department of Pediatrics, UC San Diego/Rady Children’s Hospital


  • Exploring the clear clinical endpoints to mark therapeutic success
  • Delving into what biomarkers to use for patient inclusion criteria

1:00 pm
Networking Lunch

2:00 pm Mechanism of Action of IC 100, A Humanized Monoclonal Antibody Against ASC


  • Exploring the drug discovery process: target identification and validation,
    efficacy, pathway understanding and biomarkers
  • Latest data and future directions

2:30 pm Novel Antibodies Targeting the Inflammasome to Treat Neurodegeneration


  • Discuss how the inflammasome is a promising target in neurodegenerative diseases
  • Learn how Mabylon has identified novel monoclonal antibodies that hold
    promise for the treatment of neurodegeneration

Linking Specific Inflammasomes to Specific Diseases Using Biomarkers

3:00 pm Panel Discussion: Characterizing Rational Biomarkers and Endpoints to Close the Gap Between Inflammasome Therapeutics in Development versus Inflammasome Therapeutics Reaching Patients in Need


  • What biomarkers have been validated as clinically relevant to identify inflammasome inhibition?
  • What biomarkers are being used to measure inflammasome-related disease progression versus control of disease
    using inflammasome therapeutics?
  • What are the current approaches to biomarker selection based on clinical presence of inflammation in the
  • What emerging biomarkers should we be measuring in a phase 1 or phase 2 trials to demonstrate inflammasome
  • What needs to be done to identify biomarkers and develop validated assays that enable early intervention with
    inflammasome therapeutics in disease?
  • Given the disease opportunity presented by inflammasome therapeutics, will we ever truly be able to develop
    inflammasome therapeutics with disease-agnostic potential?

3:30 pm
Chair’s Closing Remarks & End of Summit